Prognostic Assessment of F-boronophenylalanine Positron Emission Tomography (BPA-PET) in Salvage Boron Neutron Capture Therapy for Malignant Brain Tumors

Overview

Journal Quant Imaging Med Surg

Specialty Radiology

Date 2024 Jun 7

PMID 38846276

Authors

Ko-Han Lin

Yi-Wei Chen

Ling-Wei Wang

Yuh-Feng Wang

Lien-Hsin Hu

Chien Hsin Ting

Tse-Hao Lee

Jia-Cheng Lee

Nan-Jing Peng

Affiliations

Soon will be listed here.

Abstract

Background: Boron neutron capture therapy (BNCT) stands out as a propitious anti-cancer modality. F-boronophenylalanine positron emission tomography (BPA-PET) holds the potential to ascertain the concentration of BPA within the tumor, enabling meticulous treatment planning and outcome evaluation. However, no studies have been conducted on comparing the outcomes of those treated with BNCT to those who did not undergo this therapy. This study endeavors to analyze the correlation between BPA-PET and BNCT in the context of malignant brain tumors, and assess the survival outcomes following BNCT.

Methods: A cohort study was performed on patients who underwent BPA-PET between February 2017 and April 2022 in our hospital. Patients were stratified into two groups: those subjected to BNCT (Group 1) and those not (Group 2). The tumor to normal tissue (T/N) ratio derived from BPA-PET was set at 2.5. The findings were scrutinized based on clinical follow-up. Student's -test and Chi-squared test were employed to discern differences between the groups. A cumulative survival curve was constructed employing the Kaplan-Meier method. Differences were considered statistically significant at P<0.05.

Results: In total, 116 patients with T/N ratios obtained from BPA-PET were enrolled. BNCT was administered to 58 patients, while mortality was observed in 100 patients. The median overall survival (OS) for the two groups was 8.5 and 6.0 months, respectively. The cumulative OS exhibited no significant discrepancy between the two groups, nor in their T/N ratios. Within Group 1, 44 out of 58 (75.9%) patients exhibited T/N ratios exceeding 2.5. Excluding 3 patients who expired within 3 months, 55 out of 58 patients were evaluated for response after BNCT. The objective response rate (ORR) was 30.9%. Patients achieving ORR displayed substantially higher survival rates compared to those without (median OS 13.5 . 8.3 months, P=0.0021), particularly when T/N ratio exceeded 2.5 (median OS 14.8 . 9.0 months, P=0.0199).

Conclusions: BNCT does not appear indispensable for prolonging the survival of patients afflicted with malignant brain tumors. Nevertheless, it proves advantageous when ORR is attained, a condition closely linked to the values of T/N ratio derived from BPA-PET.

Citing Articles

Nanophotonic-enhanced photoacoustic imaging for brain tumor detection.

Rizwan A, Sridharan B, Park J, Kim D, Vial J, Kyhm K J Nanobiotechnology. 2025; 23(1):170.

PMID: 40045308 PMC: 11881315. DOI: 10.1186/s12951-025-03204-5.

References

Wittig A, Sheu-Grabellus S, Collette L, Moss R, Brualla L, Sauerwein W . BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot. 2011; 69(12):1807-12. DOI: 10.1016/j.apradiso.2011.02.018. View

Wang L, Chen Y, Ho C, Liu Y, Chou F, Liu Y . Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial. Int J Radiat Oncol Biol Phys. 2016; 95(1):396-403. DOI: 10.1016/j.ijrobp.2016.02.028. View

Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M . Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg. 2005; 103(6):1000-9. DOI: 10.3171/jns.2005.103.6.1000. View

Fujimoto T, Suzuki M, Sudo T, Fujita I, Sakuma T, Sakurai Y . Boron neutron capture therapy for clear cell sarcoma. Appl Radiat Isot. 2020; 166:109324. DOI: 10.1016/j.apradiso.2020.109324. View

He H, Li J, Jiang P, Tian S, Wang H, Fan R . The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol. 2021; 16(1):216. PMC: 8573925. DOI: 10.1186/s13014-021-01939-7. View

Lu J, Li P, Yang Y, Wang L, Zhang Y, Zhu J . Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0233629. PMC: 7259771. DOI: 10.1371/journal.pone.0233629. View

Chang T, Chang W, Chen Y, Ho M, Chang C, Lau S . Comparison of the synthesis and biological properties of no-carrier-added and carrier-added 4-borono-2-[F]fluorophenylalanine ([F]FBPA). Nucl Med Biol. 2023; 116-117:108313. DOI: 10.1016/j.nucmedbio.2022.108313. View

Lin S, Lin C, Liao J, Peir J, Chen W, Chi C . Therapeutic efficacy for hepatocellular carcinoma by boric acid-mediated boron neutron capture therapy in a rat model. Anticancer Res. 2013; 33(11):4799-809. View

Chen Y, Lee Y, Lin C, Huang T, Ke S, Mu P . Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series. Life (Basel). 2022; 12(4). PMC: 9025803. DOI: 10.3390/life12040566. View

10.

Miyatake S, Kawabata S, Hiramatsu R, Kuroiwa T, Suzuki M, Kondo N . Boron Neutron Capture Therapy for Malignant Brain Tumors. Neurol Med Chir (Tokyo). 2016; 56(7):361-71. PMC: 4945594. DOI: 10.2176/nmc.ra.2015-0297. View

11.

Kageji T, Nagahiro S, Mizobuchi Y, Matsuzaki K, Nakagawa Y, Kumada H . Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment. J Med Invest. 2014; 61(3-4):254-63. DOI: 10.2152/jmi.61.254. View

12.

Henriksson R, Capala J, Michanek A, Lindahl S, Salford L, Franzen L . Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol. 2008; 88(2):183-91. DOI: 10.1016/j.radonc.2006.04.015. View

13.

Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y . Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2008; 91(2):199-206. DOI: 10.1007/s11060-008-9699-x. View

14.

Furuse M, Kawabata S, Wanibuchi M, Shiba H, Takeuchi K, Kondo N . Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma. Jpn J Clin Oncol. 2022; 52(5):433-440. DOI: 10.1093/jjco/hyac004. View

15.

Lan T, Chou F, Lin K, Pan P, Lee J, Huang W . Using salvage Boron Neutron Capture Therapy (BNCT) for recurrent malignant brain tumors in Taiwan. Appl Radiat Isot. 2020; 160:109105. DOI: 10.1016/j.apradiso.2020.109105. View

16.

Slatkin D . A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain. 1991; 114 ( Pt 4):1609-29. DOI: 10.1093/brain/114.4.1609. View

17.

Hiratsuka J, Kamitani N, Tanaka R, Tokiya R, Yoden E, Sakurai Y . Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT). J Radiat Res. 2020; 61(6):945-951. PMC: 7674695. DOI: 10.1093/jrr/rraa068. View

18.

Kawabata S, Miyatake S, Nonoguchi N, Hiramatsu R, Iida K, Miyata S . Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot. 2009; 67(7-8 Suppl):S15-8. DOI: 10.1016/j.apradiso.2009.03.015. View

19.

Ishiwata K . 4-Borono-2-F-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research. Ann Nucl Med. 2019; 33(4):223-236. PMC: 6450856. DOI: 10.1007/s12149-019-01347-8. View

20.

Chanana , Capala , Chadha , Coderre , DIAZ , Elowitz . Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery. 1999; 44(6):1182-92; discussion 1192-3. DOI: 10.1097/00006123-199906000-00013. View